ES2193114T3 - Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide. - Google Patents

Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide.

Info

Publication number
ES2193114T3
ES2193114T3 ES00985268T ES00985268T ES2193114T3 ES 2193114 T3 ES2193114 T3 ES 2193114T3 ES 00985268 T ES00985268 T ES 00985268T ES 00985268 T ES00985268 T ES 00985268T ES 2193114 T3 ES2193114 T3 ES 2193114T3
Authority
ES
Spain
Prior art keywords
octreotide
intravenous
pharmaceutical formulation
intramuscular administration
stable pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00985268T
Other languages
English (en)
Inventor
Obiols Berta Ponsati
Farres Gemma Jodas
Rodriguez Francisco J Clemente
Fernandez Sergi Pavon
Cabado Jordi Bacardit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipotec SA
Original Assignee
Lipotec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipotec SA filed Critical Lipotec SA
Application granted granted Critical
Publication of ES2193114T3 publication Critical patent/ES2193114T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/16—Somatostatin; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulación farmacéutica estable para la administración intravenosa o intramuscular de Octreotide, o cualquiera de sus sales farmacéuticamente aceptables, caracterizada porque como vehículo para la inyección del péptido o sus sales farmacéuticamente aceptables contiene glicina en concentraciones de 10 a 60 mM y solución acuosa de ácido clorhídrico en una cantidad suficiente para ajustar el pH de la formulación a valores entre 3,0 y 4,2.
ES00985268T 1999-12-17 2000-12-15 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide. Expired - Lifetime ES2193114T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009902769A ES2167189B1 (es) 1999-12-17 1999-12-17 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos

Publications (1)

Publication Number Publication Date
ES2193114T3 true ES2193114T3 (es) 2003-11-01

Family

ID=8310959

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009902769A Expired - Fee Related ES2167189B1 (es) 1999-12-17 1999-12-17 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
ES00985268T Expired - Lifetime ES2193114T3 (es) 1999-12-17 2000-12-15 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES009902769A Expired - Fee Related ES2167189B1 (es) 1999-12-17 1999-12-17 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos

Country Status (13)

Country Link
US (1) US6521599B2 (es)
EP (1) EP1153615B1 (es)
JP (1) JP4912551B2 (es)
AT (1) ATE233105T1 (es)
AU (1) AU763779B2 (es)
BR (1) BR0008249A (es)
CA (1) CA2362772C (es)
DE (1) DE60001489T2 (es)
DK (1) DK1153615T3 (es)
ES (2) ES2167189B1 (es)
MX (1) MXPA01008349A (es)
PT (1) PT1153615E (es)
WO (1) WO2001043776A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003293196A1 (en) * 2002-12-23 2004-07-29 Vical Incorporated Method for producing sterile polynucleotide based medicaments
PE20050285A1 (es) 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
JP2010538092A (ja) * 2007-09-07 2010-12-09 ユナイテッド セラピューティクス コーポレーション グラム陰性菌に対して選択的殺菌活性を有するバッファー溶液およびそれを使用する方法
CN102416001B (zh) * 2011-12-09 2013-06-05 重庆煜澍丰医药有限公司 一种注射用醋酸奥曲肽冻干粉针剂及其制备方法
CN111346214A (zh) * 2020-05-13 2020-06-30 吉林吉力生物技术研究有限公司 一种动物注射用醋酸奥曲肽冻干粉针剂及其制备方法和应用
CN114146054B (zh) * 2020-09-07 2022-12-02 深圳市健元医药科技有限公司 一种醋酸奥曲肽注射液的制备工艺
CN114288385B (zh) * 2021-12-27 2024-01-19 苏州天马医药集团天吉生物制药有限公司 一种醋酸奥曲肽制剂的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3845000C2 (de) * 1987-07-10 1998-11-19 Novartis Ag Anwendung von Octreotid zur Behandlung von Brustkrebs
TW249202B (es) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
AU3257297A (en) * 1996-06-11 1998-01-07 Novartis Ag Combination of a somatostatin analogue and a rapamycin

Also Published As

Publication number Publication date
AU763779B2 (en) 2003-07-31
BR0008249A (pt) 2001-10-30
DK1153615T3 (da) 2003-06-23
DE60001489D1 (de) 2003-04-03
CA2362772A1 (en) 2001-06-21
US6521599B2 (en) 2003-02-18
ES2167189A1 (es) 2002-05-01
WO2001043776A1 (es) 2001-06-21
PT1153615E (pt) 2003-06-30
ES2167189B1 (es) 2003-04-01
JP4912551B2 (ja) 2012-04-11
AU2173601A (en) 2001-06-25
JP2003517024A (ja) 2003-05-20
MXPA01008349A (es) 2004-03-19
CA2362772C (en) 2010-03-16
ATE233105T1 (de) 2003-03-15
EP1153615B1 (en) 2003-02-26
US20020128204A1 (en) 2002-09-12
EP1153615A1 (en) 2001-11-14
DE60001489T2 (de) 2003-12-04

Similar Documents

Publication Publication Date Title
ES2526707T3 (es) Purificación y estabilización de péptidos y proteínas en agentes farmacéuticos
ES2244831T5 (es) Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica
KR920019371A (ko) 안정화된 인자 ⅷ 제제
ATE204467T1 (de) Orale darreichungsform
CY1114000T1 (el) Σταθεροποιημενα διαλυματα τεριπαρατιδης
NO20022264D0 (no) Farmasöytisk blanding inneholdende tolterodin, samt anvendelse derav
EA200200106A1 (ru) Фармацевтическая композиция леводопа/карбидопа/энтакапон
TR200103613T2 (tr) Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
HUT75684A (en) Parenteral solutions of diclofenac salts
KR970061270A (ko) 히토성장호르몬을 함유하는 의약제제
HU9302007D0 (en) Method for producing pharmaceutical preparatives containing 2-|n-(2-amino-ethyl)-amino¨-acetic acid derivatives
ES2193114T3 (es) Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide.
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
DE69430416T2 (de) Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen
ES2242973T3 (es) Utilizacion de antagonistas peptidicos de bradiquinina para la preparacion de medicamentos.
EP0296227A1 (en) Nasal delivery of amino acids
SE0000782D0 (sv) Pharmaceutical formulation and its use
IT9048063A1 (it) Composizioni farmaceutiche a base di calcitonina somministrabili per via nasale